DocWire News Editors

DocwireNews

Using a virtual visit format for caregiver appointments in patients recovering from heart failure (HF) who are transitioning to home was associated with a reduction in no-shows.In a late breaking clinical study presented at the 2019 Heart Failure Society of America <a href="https://meeting.hfsa.org/">Scientific Meeting</a> in Philadelphia, Eiran Gorodeski, MD, MPH, an associate professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and a staff cardiologist at the Cleveland Clinic&rsquo;s Heart and Vascular Institute, presented the results of the Virtual Visits in Heart Failure Care Transitions (ViV-HF) study, which aimed to quantify the extent to which virtual visits in substitution for in-person clinical appointments with caregivers would improve no-show rates.The study included patients hospitalized for HF who had been discharged to <a href="https://www.docwirenews.com/docwire-pick/future-of-medicine-picks/first-ai-wearable-approved-by-fda-for-home-use-monitoring-vitals/">home</a>. Patients received either virtual visits (n=52) or in-person visits (n=56). The primary study outcome was no-show rates at seven days post-discharge, with clinical outcomes of hospital readmission, emergency department visit, or death.According to the study results, the primary outcome did not reach statistical significance (RR=0.69; 95% CI, 0.44-1.09; P=0.12). Gorodeski did note that while not statistically significant, there was a more than 30% decrease in the no-show rate. There were no differences between study groups for hospital readmission, ER visits, or death individually.&ldquo;We proved the feasibility of substituting in-person visits with virtual visits for patients transitioning from hospital-to-home after hospitalization for HF,&rdquo; Gorodeski concluded. &ldquo; This strategy led to a reduction of no-show rates.&rdquo;He went on to note that the reduction &ldquo;was not statistically significant due to lower than anticipated event rates in the control arm, suggesting that the study was underpowered (a type II error).&rdquo;Regarding future directions, a larger trial is warranted, Gorodeski said.&ldquo;Our study suggests that a strategy of post-discharge virtual visits in patients hospitalized for HF,&rdquo; he added. &ldquo; This strategy may reduce post-discharge appointment no-show rates. This needs to be studied further in larger appropriately powered clinical trials.&rdquo;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
&#8294;<a href="https://twitter.com/EiranGorodeski?ref_src=twsrc%5Etfw">@EiranGorodeski</a>&#8297; presents Late Breaker at <a href="https://twitter.com/hashtag/HFSA2019?src=hash&amp;ref_src=twsrc%5Etfw">#HFSA2019</a> &ndash; the CCF feasibility experience with virtual HF visits, safe and trend reduction of no show rates observed. Look forward to next steps &ndash; randomized trial powered to better understand benefits and risks! <a href="https://t.co/ytGgi1dyOI">pic.twitter.com/ytGgi1dyOI</a>
&mdash; Jerry Estep (@JerryEstepMD) <a href="https://twitter.com/JerryEstepMD/status/1173608143764578304?ref_src=twsrc%5Etfw">September 16, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/EiranGorodeski?ref_src=twsrc%5Etfw">@EiranGorodeski</a> presents VIV-HF study from <a href="https://twitter.com/ClevelandClinic?ref_src=twsrc%5Etfw">@ClevelandClinic</a> at <a href="https://twitter.com/hashtag/HFSA2019?src=hash&amp;ref_src=twsrc%5Etfw">#HFSA2019</a> LBCT packed room showing feasibility &amp; safety of virtual visits after <a href="https://twitter.com/hashtag/heartfailure?src=hash&amp;ref_src=twsrc%5Etfw">#heartfailure</a> discharge. Excellent discussions in logistics, challenges, and future directions. <a href="https://twitter.com/CCFcards?ref_src=twsrc%5Etfw">@CCFcards</a> @lam_mph <a href="https://t.co/XSFBxcjy60">pic.twitter.com/XSFBxcjy60</a>
&mdash; W. H. Wilson Tang, MD (@WilsonTangMD) <a href="https://twitter.com/WilsonTangMD/status/1173609290730545154?ref_src=twsrc%5Etfw">September 16, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Thank you Jerry for your support and encouragement along the way!! <a href="https://twitter.com/WilsonTangMD?ref_src=twsrc%5Etfw">@WilsonTangMD</a> <a href="https://twitter.com/rcstarling?ref_src=twsrc%5Etfw">@rcstarling</a> What an honor to stand on the podium in this conference. <a href="https://twitter.com/hashtag/grateful?src=hash&amp;ref_src=twsrc%5Etfw">#grateful</a>
&mdash; Eiran Gorodeski, MD, MPH (@EiranGorodeski) <a href="https://twitter.com/EiranGorodeski/status/1173609567449755650?ref_src=twsrc%5Etfw">September 16, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Virtual Visits or In-Person? The ViV-HF Study

HFSA 19

Using a virtual visit format for caregiver appointments in patients recovering from heart failure (HF) who are transitioning to home was associated with a reduction in ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe